The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

INAVO120 phase 3 trial: Subgroup analyses of Asian patients (pts) with PIK3CA-mutated (mut), hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).

Yoon Sim  Yap

Honoraria - AstraZeneca; Daiichi Sankyo; DKSH; Gilead Sciences; Menarini; Novartis; Olema Oncology; Pfizer; Puma Biotechnology; Roche

Research Funding - Merck Sharp & Dohme (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; DKSH; Novartis; Roche

Other Relationship - F. Hoffmann LaRoche